<DOC>
	<DOC>NCT01958814</DOC>
	<brief_summary>randomized double-blind controlled study in parallel groups Salbutamol is a β2 mimetic short-acting to be administered by nebulization in this study. During this administration, non invasive ventilation for the patient will be continued.</brief_summary>
	<brief_title>Beta Agonist Nebulization in Non Invasively Ventilated COPD Patients: Safety, and Therapeutic Efficacy Range.</brief_title>
	<detailed_description>Randomization will focus on the treatment administered (placebo or salbutamol ). After the first phase , a switch will be set up for each patient , retaining the blind it will be administered salbutamol (for those who received placebo in the first phase ) or placebo (for those receiving salbutamol ) .</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Patient over 18 years old Patient with BPCO, defined: by an irreversible obstructive syndrome and\or by different arguments (histories, symptoms, physical examination, thoracic radiography, gas of the blood) Decompensation of this BPCO in the form of acute respiratory failure No argument for a dominant acute left cardiac insufficiency Consent signed by the patient Patient with national health assurance Contraindications in the not invasive ventilation Patient not volunteer for the realization of the spirometry Precautions for use of ß2 mimetic (engrave hyperthyroidism) Under guardianship patient or protection of justice Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>